The Association of Framingham and Reynolds Risk Scores With Incidence and Progression of Coronary Artery Calcification in MESA (Multi-Ethnic Study of Atherosclerosis)  by DeFilippis, Andrew P. et al.
S
S
M
F
U
Journal of the American College of Cardiology Vol. 58, No. 20, 2011
© 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00The Association of Framingham and
Reynolds Risk Scores With Incidence and
Progression of Coronary Artery Calcification
in MESA (Multi-Ethnic Study of Atherosclerosis)
Andrew P. DeFilippis, MD, MSC,*† Michael J. Blaha, MD, MPH,* Chiadi E. Ndumele, MD,*
Matthew J. Budoff, MD,‡ Donald M. Lloyd-Jones, MD, SCM,§ Robyn L. McClelland, PHD,
Susan G. Lakoski, MD, MS,¶ Mary Cushman, MD,# Nathan D. Wong, PHD,**
Roger S. Blumenthal, MD,* Joao Lima, MD, MBA,†† Khurram Nasir, MD, MPH‡‡
Louisville, Kentucky; Baltimore, Maryland; Los Angeles and Irvine, California; Chicago, Illinois;
Seattle, Washington; Dallas, Texas; Burlington, Vermont; and New Haven, Connecticut
Objectives The purpose of this study was to compare the association of the Framingham risk score (FRS) and Reynolds risk
score (RRS) with subclinical atherosclerosis, assessed by incidence and progression of coronary artery calcium (CAC).
Background The comparative effectiveness of competing risk algorithms for identifying subclinical atherosclerosis is unknown.
Methods MESA (Multi-Ethnic Study of Atherosclerosis) is a prospective cohort study of 6,814 participants free of baseline
cardiovascular disease. All participants underwent risk factor assessment, as well as baseline and follow-up CAC
testing. We assessed the performance of the FRS and RRS to predict CAC incidence and progression using rela-
tive risk and robust linear regression.
Results The study population included 5,140 individuals (mean age 61  10 years, 47% males, mean follow-up: 3.1  1.3
years). Among 53% of subjects (n  2,729) with no baseline CAC, 18% (n  510) developed incident CAC. Both the
FRS and RRS were significantly predictive of incident CAC (relative risk: 1.40 [95% confidence interval (CI): 1.29 to
1.52] and 1.41 [95% CI: 1.30 to 1.54] per 5% increase in risk, respectively) and CAC progression (mean CAC score
change: 6.92 [95% CI: 5.31 to 8.54] and 6.82 [95% CI: 5.51 to 8.14] per 5% increase). Discordance in risk category
classification (10% or 10% per 10-year coronary heart disease risk) occurred in 13.7%, with only the RRS consis-
tently adding predictive value for incidence and progression of CAC. These subclinical atherosclerosis findings are sup-
ported by a coronary heart disease events analysis over a mean follow-up of 5.6  0.7 years.
Conclusions Both the RRS and FRS predict onset and progression of subclinical atherosclerosis. However, the RRS may pro-
vide additional predictive information when discordance between the scoring systems exists. (J Am Coll Cardiol
2011;58:2076–83) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.022Coronary heart disease (CHD) is the leading cause of death
for men and women in the United States (1). The National
Cholesterol Education Program (NCEP) Adult Treatment
Panel III (ATP-III) guidelines recommend that all adults
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November 8, 2011:2076–83 FRS, RRS, and CAC Progressionprotein cholesterol, smoking status, systolic blood pressure,
and antihypertensive therapy to estimate a 10-year risk of a
myocardial infarction (MI) or death occurring as a result of
CHD. The ATP-III guidelines set thresholds for lipid
treatment based on the 10-year CHD risk estimated by the
FRS.
In an effort to improve cardiovascular disease (CVD) risk
prediction, the Reynolds risk score (RRS) was derived in a
cohort of 25,000 healthy U.S. women (2). The RRS
includes traditional risk factors used in the FRS and adds
parental family history of premature CHD and high-
sensitivity C-reactive protein. This, and an RRS calibrated
for men, provided superior prediction of CVD events
compared with the FRS model in 2 studies (2,3). Notably,
the RRS was developed and tested in predominantly non-
Hispanic white populations.
The underlying pathophysiology of most CHD events,
atherosclerosis, now can be measured noninvasively, includ-
ing via quantification of coronary artery calcification (CAC)
as assessed by computed topography. Identification of indi-
viduals with subclinical atherosclerosis, via CAC, has been
shown to predict future cardiovascular events in multiple
asymptomatic populations, including the young (40 years
of age), the middle aged (50 to 70 years of age), the elderly
(70 years of age), men, and women (4–12). Serial CAC
easurements may provide information on disease progres-
ion; importantly, CAC progression has been shown to be a
owerful predictor of future CVD events (4,13–15).
Clinical CHD risk assessment scores correlate with the
resence and burden of atherosclerosis identified by these
oninvasive methods (14). However, recent studies have
uggested that the FRS may misclassify both subclinical and
linical CHD risk in some individuals (16,17). These
naccuracies may be particularly pronounced among women,
ho rarely have a risk estimate high enough to meet
TP-III treatment thresholds. As a result, some individuals
ho do not qualify for primary prevention pharmacothera-
ies in fact may have advanced subclinical atherosclerosis
18,19).
We evaluated the associations of the FRS and RRS with
ncident and progression of subclinical atherosclerosis, as
stimated by CAC, in nondiabetic MESA (Multi-Ethnic
tudy of Atherosclerosis) participants with emphasis on
nstances where the scoring systems provided discordant
esults. The MESA cohort is ideal for studying these
elationships because of its large size, sex balance, multieth-
ic composition, serial measures of subclinical atherosclero-
is, and rigorous assessment of CHD events.
ethods
he MESA is a prospective epidemiologic study of the
revalence, risk factors, and progression of subclinical car-
iovascular disease in a sex-balanced, multiethnic cohort.
he study design and methods have been published previ-
usly (20). Briefly, 6,814 participants 45 to 84 years of age oho identified themselves as
hite, African American, His-
anic, or Chinese were recruited
rom 6 U.S. communities from
000 through 2002. Participants
ere free of clinical cardiovascu-
ar disease (MI, angina, stroke,
ransient ischemic attack, heart
ailure, atrial fibrillation, revascu-
arization, valve replacement,
acemaker or defibrillator im-
lantation, or taking nitroglyc-
rin) at enrollment. All partici-
ants gave informed consent,
nd the study protocol was ap-
roved by the institutional review
oard at each site.
Medical history, anthropo-
etric measurements, and labo-
atory data for the present anal-
sis were assessed as described
reviously (20). Parental history of CHD was considered
remature according to NCEP ATP-III guidelines (age
55 years in men, 65 years in women).
FRS was calculated in accordance with NCEP ATP-III
uidelines (1). Because the NCEP ATP-III FRS calcula-
ion does not include adults with diabetes (1), participants
ith diabetes were not included in this study. Additionally,
he FRS and RRS algorithms are applicable only for those
ounger than 80 and 81 years, respectfully; therefore,
articipants 80 (or 81) to 85 years were assigned a risk as
hough they were 79 (or 80) years of age. Otherwise, the
ex-specific RRS was calculated as described by Ridker et al.
2,3).
easurement of coronary artery calcium. Coronary ar-
ery calcium was measured using either electron beam
omputed tomography (3 sites) or multidetector computed
omography (3 sites). Participants were scanned twice con-
ecutively, and each scan was read by a single trained
hysician–reader (M.J.B.) independently at a centralized
eading center (Harbor-UCLA Medical Center/Los Ange-
es Biomedical Research Institute, Torrance, California).
he methodology for acquisition and interpretation of the
cans, as well as reproducibility of the readings, has been
eported previously (21). The results from the 2 scans were
veraged to provide a more accurate point estimate of the
mount of calcium present.
Calcium scores were adjusted using a standard calcium
hantom that was scanned along with the participant. The
hantom contained 4 bars of known calcium density and
as used to calibrate the x-ray attenuation level between
easurements conducted on different machines (22). The
resence of CAC was defined as a volume score of more
han 0, and a minimum focus of calcification was based on
t least 4 contiguous voxels, which resulted in identification
Abbreviations
and Acronyms
ATP-III  Adult Treatment
Panel III
AU  Agatston units
CAC  coronary artery
calcification
CHD  coronary heart
disease
CI  confidence interval
CVD  cardiovascular
disease
FRS  Framingham risk
score
MI  myocardial infarction
NCEP  National
Cholesterol Education
Program
RRS  Reynolds risk scoref calcium of 1.15 mm3 for the multidetector computed
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FRS, RRS, and CAC Progression November 8, 2011:2076–83tomography scanners and 1.38 mm3 for the electron beam
computed tomography scanners. The nominal section
thickness was 3.0 mm for electron beam computed tomog-
raphy scanners and 2.5 mm for multidetector computed
tomography.
To quantify CAC progression, a second CAC measure-
ment was performed on approximately one-half of the
cohort (randomly selected) at a second examination (Sep-
tember 2002 through February 2004) and on most of the
remaining subjects at a third examination (March 2004
through October 2005). A small portion of subjects under-
went their second CAC measurement at examination 4
(October 2005 through February 2008), whereas approxi-
mately one-quarter of participants (randomly selected) un-
derwent a third CAC measurement at examination 4. CAC
progression was calculated between the baseline and latest
scan date, with an average time between scans of 3.1  1.3
years. CAC progression is known to be highly dependent on
time between scans. Given the difference in follow-up
duration between subjects, we adjusted for time between
scans in our regression model to factor out the importance
of this variable.
CHD events. CHD events consisted of MI, death from
CHD, definite angina, probable angina followed by coro-
nary revascularization, or resuscitated cardiac arrest. Events
were recorded over a median follow-up of 5.8 years. At
intervals of 9 to 12 months, an interviewer contacted each
participant or a family member by telephone to inquire
about interim hospital admissions, outpatient diagnoses of
CHD, and deaths. To verify self-reported diagnoses, copies
were requested of all death certificates and medical records
for all hospitalizations and outpatient cardiovascular diag-
noses. Next-of-kin interviews for out-of-hospital cardiovas-
cular deaths were obtained. The MESA was successful in
obtaining medical records for approximately 98% of hospi-
talized CHD events and information on 95% of outpatient
cardiovascular diagnostic encounters. Follow-up telephone
interviews were completed for 92% of living participants.
Trained personnel abstracted data from medical records
reporting possible cardiovascular events. Two physician
members of the MESA mortality and morbidity review
committee independently classified each event, and if there
was disagreement, the full committee made the final clas-
sification. The diagnosis of myocardial infarction was based
on a combination of symptoms, electrocardiography find-
ings, and levels of cardiac biomarkers. The adjudicators
graded angina as definite, probable, or absent based on
clinical judgment. Angina required documentation of symp-
toms distinct from the diagnosis of MI. A classification of
definite angina additionally required objective evidence of
reversible myocardial ischemia or obstructive coronary artery
disease. The reviewers classified deaths resulting from CHD
as present or absent based on hospital records and interviews
with families. A more detailed description of the MESA
follow-up methods is available online (23). pStatistical analysis. We used chi-square tests for categorical
variables and the t test or analysis of variance for continuous
variables to assess for baseline differences in demographics and
cardiovascular risk factors between participants across FRS and
RRS categories (10% and 10%).
Changes in CAC were defined in 2 ways, as previously
escribed by Kronmal et al. (24): incident CAC, defined as
etectable CAC at the follow-up examination (examination
, 3, or 4) in a participant free of CAC at baseline; and
hange in CAC Agatston score in participants who had
etectable CAC at examination 1. The 2 CAC endpoints
ere modeled separately. The probability of incident CAC
as modeled as a function of covariates using a generalized
inear model with log link and binomial error distribution
relative risk regression). Relative risk regression was used
ather than logistic regression because the incidence of new
alcification was 10%, so the odds ratio would overesti-
ate the relative risk. To estimate the progression of CAC
mong those with detectable CAC at baseline, we used
ultivariate-adjusted robust linear regression. We per-
ormed a robust regression using iteratively reweighted least
quares, that is, we assigned a weight to each observation,
ith higher weights given to better behaved observations.
odels were adjusted for race, MESA site, and follow-up
uration.
The practical clinical application of cardiovascular risk
core calculation is to categorize individuals into risk cate-
ories. Numerous national consensus guideline recommen-
ations are based on risk categories, and therefore individ-
als who have discordant classification based on the risk
rediction model used would be impacted most by which
rediction model was used to make guideline-driven treat-
ent recommendations. Therefore, the groups of individ-
als who were classified into a different risk category, 10%
r 10% risk, depending on which risk prediction model
as applied (discordant risk score prediction), were evalu-
ted for a difference in the study outcome variables (incident
AC and CAC progression). If the discordant risk predic-
ion group predicted more or less risk than the risk category
or which it was being compared (the concordant higher or
ower risk group) and revealed more or less incident CAC,
AC progression, or both than predicted by the risk
rediction model being evaluated, then we concluded that
he model being evaluated added additional predictive
nformation.
Hazard ratios for incident CHD events were calculated
sing Cox proportional hazards regression per 5% increase
n risk prediction score for both the RRS and FRS. In a
imilar fashion, hazard ratios were calculated for incident
HD events among those with a risk prediction score of
10% versus 10% using both the RRS and the FRS.
azard ratios for incident CHD among those with disco-
rdinate risk score classification were calculated using RRS
10% and FRS 10% as the reference group. The overall
iagnostic performance of each risk prediction model to
redict CHD as a continuous variable or dichotomous
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November 8, 2011:2076–83 FRS, RRS, and CAC Progressionvariable was evaluated by comparing c-indexes for each
model.
All statistical analyses were completed using Stata soft-
ware version 9 (StataCorp, College Station, Texas).
Results
Of the 6,814 MESA participants, 767 were excluded
because of missing follow-up CAC testing, 684 because of
baseline diabetes, and 223 because of a missing variable of
interest. The final study population included 5,140 individ-
uals with characteristics shown in Table 1 (mean age 61 
10 years, 47% males, mean follow-up 3.1  1.3 years).
Baseline CharacteristicsTable 1 Baseline Characteristics
Baseline Characteristics
Study Population
(n  5,140)
Age (yrs) 61 10
Male 47
Race
White 42
Chinese 12
African American 25
Hispanic 21
Family history of heart attack* 9
Current smokers 12
Hypertension 41
Systolic blood pressure (mm Hg) 125 21
BMI (kg/m2) 28 5
Total cholesterol (mg/dl) 195 35
LDL 118 31
HDL 52 15
Triglycerides (mg/dl) 109 (76–157)
hsCRP (mg/l) 1.8 (0.8–4.1)
CAC 0 47
Baseline volume score (among those with CAC 0) 230 408
Baseline Agatston score (among those with CAC 0) 261 491
Values are mean  SD, %, or median (interquartile range). *Defined as a cardiovascular event in
male parent younger than 55 years and a female parent younger than 65 years.
BMI body mass index; CAC coronary artery calcification; hsCRP high-sensitivity C-reactive
protein; HDL  high-density lipoprotein; LDL  low-density lipoprotein.
Relative Risk of Incident CAC Associated With Increasing Risk CatTable 2 Relative Risk of Incident CAC Associated With Increas
FRS (Continuous*) RRS (C
Total population 1.40 (1.29–1.52) 1.41 (1
Race†
White 1.52 (1.39–1.80) 1.53 (1
Chinese 1.34 (1.06–1.70) 1.42 (1
African American 1.34 (1.16–1.54) 1.42 (1
Hispanic 1.37 (1.17–1.60) 1.29 (1
Interaction for race (p value) 0.09
Sex
Female 1.57 (1.37–1.79) 1.57 (1
Male 1.28 (1.15–1.43) 1.30 (1
Interaction for sex (p value) 0.006
Values are adjusted for race, Multi-Ethnic Study of Atherosclerosis site, and follow-up duration and
linear model and binomial error distribution adjusting for covariates. *For every 5% increase in predicted
FRS  Framingham risk score; RRS  Reynolds risk score; other abbreviation as in Table 1.Overall, 53% (n  2,729) had no detectable CAC at
baseline, of which 18% (n  510) had incident CAC at
follow-up examinations. Of those with no detectable CAC
at baseline, 2,244 (82%) had FRS 10% and RRS 10%,
109 (4%) had FRS 10% and RRS 10% 158 (6%) had
FRS 10% and RRS 10%, and 218 (8%) had FRS 10%
and RRS 10%.
The FRS and the RRS were associated with incidence
and progression of CAC of similar magnitude and statistical
significance (Tables 2 and 3) when assessed as both contin-
uous (per 5% increase in predicted event rate) and dichot-
omized (10% or 10% risk) variables. Stratification of
these results by race reveled relative risk ratios for incident
CAC that were similar to those of the total population;
additionally, the interaction term for race was not significant
in multiple analyses (Table 2). When stratified by sex, the
relative risk for developing CAC for those classified as
intermediate to high risk (10%) compared with those
classified as low risk (10%) by the FRS was 2.41 (95%
confidence interval [CI]: 1.57 to 3.72) for women and 1.62
(95% CI: 1.16 to 2.27) for men (p  0.07 for interaction).
he respective relative risks by the RRS were 2.50 (95% CI:
.63 to 3.41) for women and 2.40 (95% CI: 1.68 to 3.41) for
en (p  0.30 for interaction) (Table 2). Similar sex-
pecific findings were observed for both risk prediction
cores when assessed as a continuous variable (Table 2).
Among those with baseline CAC 0, the mean change
n CAC score consistently was greater among white persons
s compared with Chinese, African Americans, and His-
anics when evaluated as a continuous or dichotomized
ariable (more or less than a risk prediction of 10% by RRS
r FRS) (Table 3). When stratified by sex, the mean
ncremental change in CAC score for those classified as
ntermediate to high risk (10%) compared with those
lassified as low risk (10%) by the FRS was 8.69 Agatston
nits (AU) (95% CI: 0.40 to 16.89) for women and 18.79
U (95% CI: 10.85 to 26.66) for men (p  0.39 for
nteraction). The respective mean incremental change in
AC score by the RRS was 14.33 AU (95% CI: 6.92 to
ies According to FRS and RRS Classificationisk Categories According to FRS and RRS Classification
ous*) FRS >10% vs. FRS <10% RRS >10% vs. RRS <10%
.54) 2.05 (1.58–2.63) 2.55 (1.97–3.31)
.79) 2.51 (1.60–3.92) 2.99 (1.90–4.69)
.75) 1.89 (0.83–4.29) 2.38 (1.03–5.47)
.62) 1.96 (1.25–3.07) 2.61 (1.66–4.10)
.54) 1.75 (1.06–2.89) 2.06 (1.21–3.52)
0.38 0.40
.80) 2.41 (1.57–3.72) 2.50 (1.63–3.41)
.45) 1.62 (1.16–2.27) 2.40 (1.68–3.41)
0.07 0.30
ented as relative risk ratios (95% confidence intervals), having been assessed using a generalizedegoring R
ontinu
.30–1
.30–1
.15–1
.25–1
.08–1
0.45
.38–1
.17–1
0.01
are pres
risk. †Race not adjusted in multivariate-adjusted robust linear regression.
n.
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FRS, RRS, and CAC Progression November 8, 2011:2076–8321.73) for women and 23.38 AU (95% CI: 15.43 to 31.31)
for men (p  0.72 for interaction) (Table 3). Differences in
the prediction of CAC progression by sex were not observed
when applying the FRS or FRS as a continuous variable
(Table 3).
Discordance in risk category classification (10% or
10% CHD risk) between the FRS and the RRS occurred
in 13.7% of participants. Of those classified with predicted
risk of 10% by the FRS, 369 (7.2%) were classified as
intermediate to high risk (10%) by the RRS; these
participants had a relative risk of 2.41 (95% CI: 1.57 to
3.72) of having incident CAC compared with those classi-
fied as low risk (10%) by both scoring systems (Table 4).
These subjects also had a CAC progression score of 19 AU
higher (95% CI: 12 to 26) as compared with those who were
Mean Change in CAC Score (Agatston Units) Associated With IncrAccording to FRS and RRS ClassificationTable 3 Mean Change in CAC Score (Agatston Units) AssociatAccording to FRS and RRS Classification
FRS (Continuous*) RRS (C
Total population 6.9 (5.3 to 8.5) 6.8 (5
Race†
White 10.1 (7.2 to 13.0) 10.1 (7
Chinese 3.9 (0.6 to 7.1) 6.0 (3
African American 4.5 (1.2 to 7.7) 5.3 (2
Hispanic 5.8 (2.9 to 8.7) 2.3 (
Interaction for race (p value) 0.05 0
Sex
Female 6.2 (3.4 to 8.9) 4.4 (2
Male 5.9 (3.5 to 8.3) 6.5 (4
Interaction for sex (p value) 0.30
Values are mean (95% confidence interval). Analysis is robust linear regression, adjusted for race
increase in predicted risk. †Race not adjusted for in multivariable adjusted robust linear regressio
Abbreviations as in Tables 1 and 2.
Relative Risk of Incident CAC and Mean ChangeWith Varying FRS an RRS Groups According toClass fi d by , Res ectively
Table 4
Relative Risk of Inci ent CA and M
With Varying FRS and RRS Groups
Classified by FRS and RRS, Respec
In
Rela
FRS: 10-yr CHD risk 10% (n  3,847)
RRS 10% (n  3,478) 1.00 (
RRS 10% (n  369; 7.2% discordance) 2.41 (
RRS continuous* 1.12 (
FRS: 10-yr CHD risk 10% (n  1,293)
RRS 10% (n  336; 6.5% discordance) 0.54 (
RRS 10% (n  957) 1.00 (
RRS continuous* 1.04 (
RRS: 10-yr CHD risk 10% (n  3,814)
FRS 10% (n  3,478) 1.00 (
FRS 10% (n  336; 6.5% discordance) 1.47 (
FRS continuous* 1.09 (
RRS: 10-yr CHD risk 10% (n  1,326)
FRS 10% (n  369; 7.2% discordance) 0.86 (
FRS 10% (n  957) 1.00 (
FRS continuous* 1.02 (Values are adjusted for race, Multi-Ethnic Study of Atherosclerosis site, and f
CHD  coronary heart disease; CI  confidence interval; other abbreviatioclassified as low risk by both scoring systems (Table 4). Of
those classified with predicted risk 10% by the FRS, 336
(6.5%) were classified low risk (10%) by the RRS; these
participants had a relative risk of 0.54 (95% CI: 0.33 to
0.88) of having incident CAC compared with those classi-
fied as intermediate to high risk (10%) by both scoring
systems (Table 4). These subjects also had a CAC progres-
sion score of 16 AU lower (95% CI: 30 to 1) as
compared with those who were classified as intermediate to
high risk by both scoring systems (Table 4).
Of those classified with predicted risk 10% by RRS,
336 (6.5%) were classified as intermediate to high risk
(10%) by the FRS; these participants had a relative risk of
1.47 that did not meet statistical significance (95% CI: 0.98
to 2.21) for the development of incident CAC compared
g Risk Categoriesith Incre sing Ri k Categories
ous*) FRS >10% vs. FRS <10% RRS >10% vs. RRS <10%
.1) 17.8 (12.5 to 23.0) 21.6 (16.5 to 26.8)
2.4) 24.5 (15.3 to 33.8) 34.5 (25.5 to 43.6)
.0) 15.7 (5.2 to 26.2) 17.0 (6.6 to 27.4)
.0) 9.3 (1.7 to 20.2) 20.8 (10.2 to 31.3)
4.7) 15.3 (6.0 to 24.6) 3.0 (6.6 to 12.6)
0.03 0.0001
.3) 8.7 (0.4 to 16.9) 14.3 (6.9 to 21.7)
.4) 18.8 (10.9 to 26.7) 23.4 (15.4 to 31.3)
0.39 0.72
-Ethnic Study of Atherosclerosis site, and follow-up duration. *Change in CAC score for every 5%
AC Score- and High-Risk GroupsChange in CAC Score
rding to Low- and High-Risk Groups
CAC,
isk Ratio
CI)
CAC Score Change,
Robust Linear Regression Coefficient
(95% CI)
nce group) 0 (reference group)
o 3.72) 19 (12 to 26)
o 1.16) 2.03 (1.50 to 2.58)
o 0.88) 16 (30 to1)
nce group) 0 (reference group)
o 1.06) 1.01 (0.45 to 1.57)
nce group) 0 (reference group)
o 2.21) 11 (3 to 19)
o 1.12) 1.88 (1.21 to 2.56)
o 1.47) 6 (18 to 7)
nce group) 0 (reference group)
o 1.05) 0.30 (0.39 to 0.97)easind W
ontinu
.5 to 8
.8 to 1
.1 to 9
.6 to 8
0.4 to
.0001
.4 to 6
.5 to 8
0.45
, Multiin CLowean
Acco
tively
cident
tive R
(95%
refere
1.57 t
1.09 t
0.33 t
refere
1.00 t
refere
0.98 t
1.06 t
0.52 t
refere
0.99 tollow-up duration. *For every 1% increase in risk prediction score.
ns as in Tables 1 and 2.
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November 8, 2011:2076–83 FRS, RRS, and CAC Progressionwith those classified as low risk by both scoring systems
(Table 4). However, these subjects had a CAC progression
score of 11 AU higher (95% CI: 3 to 19) compared with
those who were classified as low risk by both scoring systems
(Table 4). Of those classified with predicted risk of more
than 10% by the RRS, 369 (7.2%) were classified low risk
(10%) by the FRS; these participants had no statistical
difference in progression of or development of incident
CAC when compared with those classified as low risk by
both scoring systems (6 [95% CI: 18 to 7] progression;
0.86 [95% CI: 0.52 to 1.47] incident) (Table 4).
Participants with concordant risk prediction classification
of intermediate to high risk (10%) category by both scores
had a higher odds ratio for incident CAC and mean change
in CAC score than those classified as intermediate to high
risk (10%) by one risk prediction model, but low risk (10%) by
he other risk prediction model (Table 5).
A total of 135 participants (2.63%) had CHD events
uring a mean follow-up of 5.6  0.7 years. Adjusting for
ace, the hazard ratios for any incident CHD event with
very 5% increase in FRS and RRS were 1.42 (95% CI: 1.33
o 1.52) and 1.32 (95% CI: 1.27 to 1.41), respectively. The
elative risk of CHD developing for those with intermediate
o high risk (10%) compared with those considered low
isk (10%) by the FRS was 3.62 (95% CI: 2.57 to 5.08).
he respective relative risk for the RRS was 4.58 (95% CI:
.24 to 6.48). The c-indexes for the FRS and RRS for
redicting incident CHD events were not significantly
ifferent when assessed as either as a continuous variable
0.71 vs. 0.75, p  0.27) or dichotomous variable (0.71 vs.
.72, p  0.21). Analysis of the 6.5% of subjects classified as
ow risk by the RRS but as high risk (10%) by the FRS and
he 7.2% of subjects classified as low risk by the FRS but as
igh risk (10%) by the RRS was limited by the low
bsolute number of CHD events, but was consistent with
he differences found between these 2 risk scores in the
rediction of subclinical atherosclerosis, as assessed by
ncident and progression of CAC (Table 6). Excluding
articipants older than age 79 years or who did not report a
arental history of CVD at examination 1, but who reported
Relative Risk for Incident and MeanChange in CAC Score Among ParticipantsWith Discoordinate Risk Pre iction Scores
Table 5
Rel ive Risk for Incident and Mean
Change in CAC Score Among Participants
With Discoordinate Risk Prediction Scores
Incident CAC Scores,
Relative Risk Ratio
(95% CI)
CAC Score Change
(Agatston Units),
Regression Coefficient
(95% CI)
RRS 10% and FRS 10%
(n  3,478)
1.00 (reference group) 0 (reference group)
RRS 10% and FRS 10%
(n  336)
1.48 (0.98 to 3.72) 13 (3 to 23)
RRS 10% and FRS 10%
(n  369)
2.42 (1.57 to 3.72) 22 (14 to 31)
RRS 10% and FRS 10%
(n  957)
2.74 (2.01 to 3.72) 24 (17 to 29)r
Values are adjusted for race, Multi-Ethnic Study of Atherosclerosis site, and follow-up duration.
Abbreviations as in Tables 1, 2, and 4.positive family history at examination 2, did not change
he results of the above analyses (data not shown).
iscussion
n this large multiethnic cohort, both the RRS and the FRS
re predictive of incidence and progression of subclinical
therosclerosis, as measured by CAC. Importantly, these
esults were supported by similar findings for CHD events,
nderscoring the principle that subclinical atherosclerosis is
precursor for CHD events and that the magnitude of this
isease process can be assessed by CAC progression. When
valuated as a continuous variable, the RRS and FRS
erformed equally well in the prediction of incident CAC
nd CAC progression. However, considerable reclassifica-
ion (13.7%) occurred among the risk models when classi-
ed into conventional risk categories, as is done in clinical
ractice. When classified into low- and high-risk to
ntermediate-risk groups, the RRS provided additional pre-
ictive power beyond the FRS, both for predicting incident
AC and progression of CAC. The converse was not true:
he FRS did not consistently add predictive power beyond
he RRS for predicting incident CAC, CAC progression, or
ncident CHD events. An analysis of discoordinate classi-
cation between the RRS and FRS for CHD events
evealed similar results as those seen with incident and
rogression of CAC; however, this analysis was limited by
he low number of CHD events currently present in this
ohort.
Both the FRS and RRS include sex as a weighted
ariable. In our cohort, sex-specific analyses did not reveal a
onsistent difference in either risk score’s capacity to predict
rogression or incident CAC based on sex. Both risk
rediction scores performed equally across 4 race groups for
redicting incident CAC, but predicted significantly greater
AC progression in whites as compared to Chinese, Afri-
an Americans, or Hispanics—a finding the warrants vali-
ation in independent cohorts.
The reclassification observed in our cohort was consider-
bly less than the reclassification found in the cohort used to
evelop and test the RRS; nondiabetic women classified as
ntermediate risk (10% to 20% 10-year risk of a major
ardiovascular disease event) by the FRS would be reclassi-
ed with the RRS as follows: 21% of women would be
Hazard Ratio for Incident CHDAmong P rticipants WithDiscoordinate Risk Pr diction Scores
Table 6
Hazard Ratio for Incident CHD
Among Participants With
Discoordinate Risk Prediction Scores
Incident CHD, Hazard Ratio
(95% CI)
RRS 10% and FRS 10% (n  3,478) 1.00 (reference group)
RRS 10% and FRS 10% (n  336) 1.91 (0.90–4.04)
RRS 10% and FRS 10% (n  369) 3.65 (2.09–6.39)
RRS 10% and FRS 10% (n  957) 5.47 (3.74–8.00)
Abbreviations as in Tables 2 and 4.eclassified as high risk (20% risk) and 24% of women
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FRS, RRS, and CAC Progression November 8, 2011:2076–83would be reclassified as low risk (10% risk) (2). Impor-
tantly, both the analysis of the cohort used to develop the
RRS and this analysis are limited by the fact that these 2
prediction models differ in that the RRS predicts the
composite outcome of MI, ischemic stroke, coronary revas-
cularization, and cardiovascular death, whereas the FRS was
designed to predict MI and CHD death only. Additional
limitations include an upper age limit in the FRS and RRS
algorithms of 79 and 80 years, respectively; therefore, for
participants 80 (or 81) to 85 years of age, we assigned them
a risk as though they were 79 (or 80) years of age. Detailed
family history was evaluated in the MESA at examination 2,
whereas baseline CAC was evaluated at examination 1.
However, exclusion of subjects older than 79 years or who
did not report a CHD event in any first-degree relative at
examination 1, but who had a positive family history at
examination 2, did not change the results of the analysis.
Finally, our definition of parental history of CHD is
consistent with that of the NCEP ATP-III guidelines (age
55 years in men, 65 years in women), but differs slightly
rom that used in the RRS (age60 years in men or women
or CHD or stroke). We believe this difference in defini-
ions of family history of CVD is minimal and unlikely to
etract from our results.
Although robust data exist on the prognostic value of
AC severity in predicting cardiovascular outcomes, fewer
ata exist as to whether CAC progression is informative
egarding the risk of future events. Multiple studies have
emonstrated an association between CAC progression and
everal traditional and emerging CVD risk factors in this
ohort and others (14,24,25). Emerging data now suggest
dditive value of CAC progression beyond CAC alone in
rediction of CVD events (4,13–15).
Our study findings raise 2 important questions. First, do
ardiovascular risk prediction models accurately predict the
rogression of subclinical atherosclerosis? In our study, both
he RRS and FRS were associated significantly with pro-
ression of subclinical atherosclerosis as measured by inci-
ent CAC and CAC progression. Of particular interest is
hat this association occurred in an ethnically diverse and
ex-diverse population that was unlike the cohort used to
evelop either risk score. Our incident CHD event data
ere consistent with the large body of data that demon-
trates the association of the FRS and RRS with future
ardiovascular events, but this study is unique in that it
emonstrates that these risk scores also predict progression
f subclinical atherosclerosis.
Second, are there differences in the ability of RRS and
RS to predict accurately progression of subclinical athero-
clerosis? Reclassification (13.7%) did occur among the risk
odels, and the RRS provided additional predictive power
eyond the FRS for predicting incident CAC and progres-
ion of CAC. This finding of RRS superiority in the
rediction of subclinical atherosclerosis was substantiated
urther with our finding that the RRS had additive value inredicting CHD events in individuals who had discordance
etween the 2 risk scores; the same was not true of the FRS.
onclusions
he RRS and FRS may be useful in predicting the devel-
pment and progression of subclinical atherosclerosis as
ssessed by incidence and progression of CAC. When risk
lassification differences occurred between these 2 risk
coring systems, the RRS was able to provide additional
redictive information more consistently. The importance
f these findings was supported by an analysis of the risk
odels’ ability to predict CHD events in this cohort.
urther studies are needed to delineate more clearly the role
f risk prediction models in identifying subclinical athero-
clerosis and to delineate the role of CAC progression in
isk prediction and the evaluation of treatment efficacy.
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